Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity.

Jordan KR, McMahan RH, Oh JZ, Pipeling MR, Pardoll DM, Kedl RM, Kappler JW, Slansky JE.

J Immunol. 2008 Jan 1;180(1):188-97.

2.

Vaccination of mice with baculovirus-infected insect cells expressing antigenic proteins.

Jordan KR, Crawford F, Kappler JW, Slansky JE.

Curr Protoc Immunol. 2009 Apr;Chapter 2:Unit 2.15. doi: 10.1002/0471142735.im0215s85.

3.

Acquisition of MHC:peptide complexes by dendritic cells contributes to the generation of antiviral CD8+ T cell immunity in vivo.

Smyth LA, Hervouet C, Hayday T, Becker PD, Ellis R, Lechler RI, Lombardi G, Klavinskis LS.

J Immunol. 2012 Sep 1;189(5):2274-82. doi: 10.4049/jimmunol.1200664. Epub 2012 Jul 20.

4.

Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.

Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F.

Cancer Immunol Immunother. 2004 Nov;53(11):963-77. Epub 2004 May 14.

PMID:
15146294
6.

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM.

J Immunol. 2004 Apr 1;172(7):4215-24.

7.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

André F, Chaput N, Schartz NE, Flament C, Aubert N, Bernard J, Lemonnier F, Raposo G, Escudier B, Hsu DH, Tursz T, Amigorena S, Angevin E, Zitvogel L.

J Immunol. 2004 Feb 15;172(4):2126-36.

8.

Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells.

Dolan BP, Gibbs KD Jr, Ostrand-Rosenberg S.

J Immunol. 2006 Nov 1;177(9):6018-24.

9.

Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion.

Wei J, Waithman J, Lata R, Mifsud NA, Cebon J, Kay T, Smyth MJ, Sadler AJ, Chen W.

J Immunol. 2010 Nov 15;185(10):6013-22. doi: 10.4049/jimmunol.1002129. Epub 2010 Oct 18.

10.

Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.

Kang TH, Chung JY, Monie A, Pai SI, Hung CF, Wu TC.

Gene Ther. 2010 Apr;17(4):531-40. doi: 10.1038/gt.2009.152. Epub 2009 Nov 26.

11.

Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.

Mitsui H, Inozume T, Kitamura R, Shibagaki N, Shimada S.

J Invest Dermatol. 2006 Aug;126(8):1804-12. Epub 2006 Apr 27.

12.

The relative efficiency of acquisition of MHC:peptide complexes and cross-presentation depends on dendritic cell type.

Smyth LA, Harker N, Turnbull W, El-Doueik H, Klavinskis L, Kioussis D, Lombardi G, Lechler R.

J Immunol. 2008 Sep 1;181(5):3212-20.

13.

Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.

Ikeuchi N, Futami J, Hosoi A, Noji S, Kurachi M, Ueha S, Fujii S, Yamada H, Matsushima K, Moriyasu F, Kakimi K.

Biochem Biophys Res Commun. 2010 Feb 5;392(2):217-22. doi: 10.1016/j.bbrc.2010.01.019. Epub 2010 Jan 11.

PMID:
20067764
15.

Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.

16.

In vivo splenic CD11c cells downregulate CD4 T-cell response thereby decreasing systemic immunity to gene-modified tumour cell vaccine.

Cayeux S, Bukarica B, Buschow C, Charo J, Bunse M, Dörken B, Blankenstein T.

Gene Ther. 2007 Oct;14(20):1481-91. Epub 2007 Aug 16.

PMID:
17700709
17.

Intradermal immunization with combined baculovirus and tumor cell lysate induces effective antitumor immunity in mice.

Kawahara M, Takaku H.

Int J Oncol. 2013 Dec;43(6):2023-30. doi: 10.3892/ijo.2013.2125. Epub 2013 Oct 4.

PMID:
24101126
18.
19.

Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.

Belnoue E, Di Berardino-Besson W, Gaertner H, Carboni S, Dunand-Sauthier I, Cerini F, Suso-Inderberg EM, Wälchli S, König S, Salazar AM, Hartley O, Dietrich PY, Walker PR, Derouazi M.

Mol Ther. 2016 Sep;24(9):1675-85. doi: 10.1038/mt.2016.134. Epub 2016 Jul 5.

PMID:
27377043
20.

Supplemental Content

Support Center